Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) had its target price reduced by equities research analysts at Credit Suisse Group from $12.00 to $11.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Credit Suisse Group’s price objective would suggest a potential upside of 52.35% from the stock’s previous close.
Separately, Wells Fargo & Company raised shares of Monte Rosa Therapeutics from an “equal weight” rating to an “overweight” rating and set a $18.00 target price for the company in a report on Monday, January 2nd.
Monte Rosa Therapeutics Stock Up 3.0 %
GLUE opened at $7.22 on Friday. The company has a fifty day moving average price of $6.88 and a two-hundred day moving average price of $7.75. Monte Rosa Therapeutics has a 52 week low of $5.74 and a 52 week high of $15.52.
Hedge Funds Weigh In On Monte Rosa Therapeutics
Monte Rosa Therapeutics Company Profile
Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
- Get a free copy of the StockNews.com research report on Monte Rosa Therapeutics (GLUE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.